Pharmadrug Inc.
PHRX
CNSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -2.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -2.50K |
| Cost of Revenue | -- | -- | -- | -- | 0.00 |
| Gross Profit | -- | -- | -- | -- | 0.00 |
| SG&A Expenses | 773.90K | 826.20K | 954.30K | 818.60K | 524.90K |
| Depreciation & Amortization | 47.00K | 37.80K | 28.60K | 19.30K | -600.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 892.60K | 988.80K | 1.19M | 1.01M | 650.10K |
| Operating Income | -892.60K | -988.80K | -1.19M | -1.01M | -650.10K |
| Income Before Tax | -10.47M | -10.56M | -10.77M | -10.50M | 1.08M |
| Income Tax Expenses | -742.60K | -742.60K | -742.60K | -742.60K | -- |
| Earnings from Continuing Operations | -9.73 | -9.82 | -10.03 | -9.76 | 1.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -2.08M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 44.90K | 44.90K | 44.90K | 44.90K | -- |
| Net Income | -9.68M | -9.77M | -9.98M | -9.71M | -850.90K |
| EBIT | -892.60K | -988.80K | -1.19M | -1.01M | -650.10K |
| EBITDA | -860.00K | -963.20K | -1.17M | -994.40K | -650.30K |
| EPS Basic | -0.13 | -0.13 | -0.14 | -0.14 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.13 | -0.13 | -0.14 | -0.14 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 372.98M | 319.64M | 270.06M | 225.95M | 202.51M |
| Average Diluted Shares Outstanding | 372.98M | 319.64M | 270.06M | 225.95M | 202.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
